Neoplasma. 2014;61(3):274-82. doi: 10.4149/neo_2014_035.
CD44 is one member of a big glycoprotein family involved in adhesion of cells or cells and extracellular matrix (ECM). The heavily glycosylated CD44 has been proved to be a major receptor of hyaluronan and a marker of stem cells in ovarian cancer. Here, using short hairpin (shRNA) against CD44, we demonstrate that knockdown CD44 could inhibit cancer growth efficiently compared with controls. Plasmid targeting CD44 gene (pshCD44) or non-relative control sequences (pshHK) was constructed and delivered to ovarian cancer by biodegradable poly D, L-Lactide-co-glycolide acid nanoparticles (PLGANPs). Nude mice were utilized in an intraperitoneal model of ovarian carcinomatosis to assess antitumor efficacy in vivo. Antitumor efficacy was estimated by changes in tumor weights, proliferation (Ki-67), apoptosis (TUNEL) and angiogenesis (CD31 staining and alginate-encapsulated tumor beads assay) in tumor cells. As results, pshCD44 or pshHK could be effectively transfected into SKOV-3 cells by PLGANPs. Tumor weight in pshCD44/PLGANPs group was suppressed by 45% and 50% compared with those in pshHK/PLGANPs and untreated group, respectively (Ps < 0.001). Inhibition of cell proliferation, induction of apoptosis and reduction of angiogenesis in tumor cells of pshCD44/PLGANPs group also show significant difference compared with those in control groups (Ps < 0.05), respectively. These results indicate that pshCD44 delivered by PLGANPs might be a potential approach in ovarian cancer therapy, and point towards a mechanism involving the inhibition of angiogenesis, cellular proliferation and the induction of apoptosis.
CD44 是一种参与细胞或细胞与细胞外基质(ECM)黏附的大型糖蛋白家族的成员。高度糖基化的 CD44 已被证明是透明质酸的主要受体,也是卵巢癌干细胞的标志物。在这里,我们使用针对 CD44 的短发夹(shRNA)证明,与对照相比,敲低 CD44 可以有效地抑制癌症生长。构建了针对 CD44 基因的质粒(pshCD44)或非相关对照序列(pshHK),并通过可生物降解的聚 D、L-乳酸-co-乙醇酸纳米粒(PLGANPs)递送至卵巢癌细胞。利用裸鼠建立卵巢癌腹膜转移模型,在体内评估抗肿瘤疗效。通过肿瘤重量、增殖(Ki-67)、凋亡(TUNEL)和血管生成(CD31 染色和藻酸盐包埋肿瘤珠测定)的变化来估计抗肿瘤疗效。结果表明,PSHCD44 或 PSHHK 可以通过 PLGANPs 有效地转染 SKOV-3 细胞。与 pshHK/PLGANPs 组和未处理组相比,pshCD44/PLGANPs 组的肿瘤重量分别抑制了 45%和 50%(P < 0.001)。PSHCD44/PLGANPs 组肿瘤细胞的细胞增殖抑制、凋亡诱导和血管生成减少与对照组相比也有显著差异(P < 0.05)。这些结果表明,PLGANPs 递送的 pshCD44 可能是卵巢癌治疗的一种潜在方法,并提示一种涉及抑制血管生成、细胞增殖和诱导凋亡的机制。